For the past two years, plan sponsors have approached GLP-1s like any other high-cost drug class: manage utilization, tighten prior authorization, and hope the trend stabilizes.
It won’t.
GLP-1s are not a utilization problem. They are a structural cost shift, and plan sponsors treating them tactically are already behind.
Plan sponsors are now spending an average of ~$22,000 per patient over five years on GLP-1 therapies. [1] At the same time, emerging research shows those costs are not offset by short- or mid-term medical savings, particularly for obesity treatment. The only way to get true ROI for those taking GLP-1s on the plan is with long-term engagement.
The assumption that “these drugs will pay for themselves” is not holding up, at least not on plan sponsor timelines. And yet, demand is accelerating. 72% of plan sponsors say GLP-1s are already driving healthcare costs to a great or very great extent. [2]
This is not a trend you can manage at the margins, it’s a capital allocation decision.
Most plan sponsors are asking “How do we control GLP-1 utilization?” but the better question is “Where do GLP-1 dollars generate the highest return?” because not all utilization is equal.
The same research that challenges ROI broadly also points to something more important: outcomes, and potential cost offsets, are significantly stronger in higher-risk populations, particularly those with diabetes or advanced comorbidities.
In other words, GLP-1s don’t “not work.” They’re just being deployed inefficiently.
This is where GLP-1 conversations should move; away from broad, demand-driven access and toward precision eligibility and budgeted utilization. Making use of every dollar means treating GLP-1s less like a drug benefit and more like a managed health investment.
This requires more than prior authorization. It necessitates alignment between clinical decisions and financial outcomes.
A new category of GLP-1 vendors is emerging to do exactly that.
The most effective platforms don’t just manage utilization, they are able to set utilization costs in partnership with plan actuaries, tying total anticipated cost directly to plan sponsor budget targets. From there, they identify the highest-risk members, guide appropriate access, and track outcomes over time.
Fewer members on therapy. Better outcomes per member. Predictable spend.
GLP-1s are not going away. In fact, the obesity medication class is expected to grow 212% from 2024 to 2028. 2 Demand will continue to grow and eligibility will expand. Plan sponsors who continue to treat this as a utilization problem will see rising costs with limited returns.
Those who treat it as a strategic financial decision will do something different: they will decide intentionally who gets access, at what cost, and for what outcomes.
Because the question is no longer whether to cover GLP-1s, it’s whether you can afford to do it without a strategy.
As you plan for the next year, shift the conversation: Don’t treat GLP-1s as a drug trend to manage, treat them as a fixed investment to allocate.
Because without clear guardrails around who gets access and why, rising demand will always outpace your ability to control cost.
1 | Wegovy and similar weight-loss drugs may not ‘pay for themselves’. BenefitsPRO. Allison Bell. (2026, January 14).
2 | Managing GLP-1 medications and related costs. Business Group on Health. (2026, March 2).
